Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin–5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial

A. Lamarca, D.H. Palmer, H.S. Wasan, P.J. Ross, Y.T. Ma, A. Arora, S. Falk, R. Gillmore, J. Wadsley, K. Patel, A. Anthoney, A. Maraveyas, T. Iveson, J.S. Waters, C. Hobbs, T. Macdonald, D. Ryder, J. Ramage, L.M. Davies, J.A. Bridgewater, J.W. Valle

Open source

DOI: 10.1016/j.esmoop.2026.107777
Published: 2026-07
Container: ESMO Open
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2026.107777,
  title = {Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin–5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial},
  author = {A. Lamarca and D.H. Palmer and H.S. Wasan and P.J. Ross and Y.T. Ma and A. Arora and S. Falk and R. Gillmore and J. Wadsley and K. Patel and A. Anthoney and A. Maraveyas and T. Iveson and J.S. Waters and C. Hobbs and T. Macdonald and D. Ryder and J. Ramage and L.M. Davies and J.A. Bridgewater and J.W. Valle},
  year = {2026},
  journal = {ESMO Open},
  doi = {10.1016/j.esmoop.2026.107777},
  url = {https://doi.org/10.1016/j.esmoop.2026.107777}
}

RIS

TY  - JOUR
TI  - Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin–5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial
AU  - A. Lamarca
AU  - D.H. Palmer
AU  - H.S. Wasan
AU  - P.J. Ross
AU  - Y.T. Ma
AU  - A. Arora
AU  - S. Falk
AU  - R. Gillmore
AU  - J. Wadsley
AU  - K. Patel
AU  - A. Anthoney
AU  - A. Maraveyas
AU  - T. Iveson
AU  - J.S. Waters
AU  - C. Hobbs
AU  - T. Macdonald
AU  - D. Ryder
AU  - J. Ramage
AU  - L.M. Davies
AU  - J.A. Bridgewater
AU  - J.W. Valle
PY  - 2026
JO  - ESMO Open
DO  - 10.1016/j.esmoop.2026.107777
UR  - https://doi.org/10.1016/j.esmoop.2026.107777
ER  -

APA

Lamarca, A., Palmer, D., Wasan, H., Ross, P., Ma, Y., Arora, A., Falk, S., Gillmore, R., Wadsley, J., Patel, K., Anthoney, A., Maraveyas, A., Iveson, T., Waters, J., Hobbs, C., Macdonald, T., Ryder, D., Ramage, J., Davies, L., Bridgewater, J., & Valle, J. (2026). Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin–5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial. ESMO Open. https://doi.org/10.1016/j.esmoop.2026.107777

Source records

crossref · retrieved 2026-09-26T08:50:33.841Z